Neurocrine Biosciences, Inc.

NBIX

Market Cap$14.05B

Close$

Compare Neurocrine Biosciences

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
Neurocrine Biosciences, Inc.	38	0%	15%	7.2	0.1
Market Avg	54.3	1.27%	32%	-	1.3
Healthcare Avg	39.1	1.36%	17%	7.2	1.3

$173.50

Target Price by Analysts

26.9% upsideNeurocrine Biosciences Target Price Details

$257.62

Current Fair Value

88.5% upside

Undervalued by 88.5% based on the discounted cash flow analysis.

Share Statistics

Market cap	$14.05 Billion
Enterprise Value	$12.97 Billion
Dividend Yield	$0.0 (0.0%)
Earnings per Share	$3.6
Beta	0.36
Outstanding Shares	100,637,227
Avg 30 Day Volume	786,183

Return

Return on Equity	-
Return on Assets	-
Return on Invested Capital	-

Valuation & Multiples

P/E Ratio	38.02
PEG	-24.27
Price to Sales	7.19
Price to Book Ratio	5.94
Enterprise Value to Revenue	6.54
Enterprise Value to EBIT	27.57
Enterprise Value to Net Income	35
Total Debt to Enterprise	0.01
Debt to Equity	0.05

Revenue Sources

No data

ESG Score

No data

About Neurocrine Biosciences, Inc.

CEO: Kevin Gorman